Webinar: US Post-Approval Change Strategies for Small Molecules

In today’s evolving regulatory environment, timely and compliant execution of these changes is crucial for maintaining product integrity and avoiding costly delays. Whether you're navigating updates in formulation, manufacturing processes, or packaging, understanding how to properly characterize and file these changes with the FDA is essential to avoid delays, non-compliance, or product shortages.

Through a combination of real-world case studies and expert insights, we walk you through the steps required to assess proposed post-approval changes, streamline internal processes, and submit changes effectively to regulatory authorities with confidence. You'll gain valuable knowledge on how to handle urgent modifications while ensuring your regulatory filings are accurate, compliant, and timely.

Need help navigating post-approval changes in the US?

Contact us to see how we can support your team in all aspects related to regulatory strategies to move your product through all regulatory stages.

Our Experts

  • Philip Simonson Bio Photo

    Philip Simonson

    Senior Vice President, CMC Regulatory Sciences

    View Bio

  • Gregory Kufner Bio Photo

    Gregory Kufner

    Senior Consultant CMC, Regulatory Sciences

    View Bio

Philip is the Senior Vice President for CMC Regulatory Sciences at ProPharma.  He has over 30 years of experience executing global regulatory strategies in all phases of drug development including life-cycle management. He is also accomplished in R&D program management and in the successful commercialization of enabling drug delivery technologies.  Prior to joining ProPharma, he spent more than 20 years in industry with Parke-Davis, Pfizer & Cephalon and most recently served as Vice President, Global Regulatory Affairs for ICON plc. 

Gregory is a Senior CMC Regulatory Consultant for ProPharma. He has 24 years of experience in the development, manufacturing, and troubleshooting of large and small molecule pharmaceuticals. He previously served as an Executive Director of Technical Services for Akorn Pharmaceuticals where he successfully implemented many drug product changes (API and finished product) on multiple approved drug products.